Most patients with a cardiac resynchronization therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented at the European Society of Cardiology (ESC) Congress.


Results of the PLATFORM trial indicate fractional flow reserve computed tomography (FFR-CT) can obviate the need for invasive tests in up to 61 percent of patients with chest pain and suspected coronary artery disease. The results were presented at the European Society of Cardiology (ESC) Congress 2015.



Hospital-based healthcare providers today are under greater pressure than ever to administer cost- and time-efficient cardiac care that directly enhances patient outcomes. A critical strategy for achieving these goals is the utilization of rapid point-of-care (POC) diagnostics.


An investigational material known as Bioabsorbable Cardiac Matrix (BCM), designed to prevent cardiac remodeling in heart attack patients, had no significant effect compared to a saline placebo, according to a new study.


September 2, 2015 — HeartWare International Inc. announced it entered into a definitive agreement to acquire Valtech Cardio Ltd.  Valtech is a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases – mitral valve regurgitation (MR) and tricuspid valve regurgitation (TR).



Retrieval of larger thrombi during intra-arterial treatment (IAT) is associated with improved neurological recovery after acute ischemic stroke, according to a sub-study of the MR CLEAN trial.



Findings presented at the European Society of Cardiology (ESC) Congress 2015 indicate that a small left ventricle with thick walls is the strongest predictor of morphologic remodeling in chronic ischemic heart disease patients.


Emergency department patients with chest pain suggestive of acute myocardial infarction (AMI) can be triaged more quickly and safely using a new rapid assay with refined cut-offs, German research suggests.


Automated alerts for excess fluid accumulation in the lungs did not improve outcomes for heart failure patients with implantable cardioverter defibrillators (ICDs), according to results of the OPTILINK HF trial.


The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) were showcased at the European Society of Cardiology (ESC) Congress 2015 in London.

Subscribe Now